Home›Research›Compare›Foxo4-DRI vs MOTS-c
Peptide ComparisonFoxo4-DRI vs MOTS-c
Both are Longevity & Cellular peptides.
Foxo4-DRI
Foxo4-D-Retro-Inverso
Half-life: Unknown
13 providers listed
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c
Half-life: Unknown (rapidly cleared from plasma)
181 providers listed
MOTS-c carries stronger published evidence (Cohort study, 19 key studies) than Foxo4-DRI (Review, 3); both are research compounds.
Foxo4-DRI
Evidence
MOTS-c
Evidence
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | MOTS-c |
| Lower typical price per mg | MOTS-c |
| More provider options (13 vs 181) | MOTS-c |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Foxo4-DRI
MOTS-c
Foxo4-DRI
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigat…
Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-…
MOTS-c
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resis…
LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation…
Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercis…
Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human me…
+15 more
About Foxo4-DRI
D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"
About MOTS-c
Mitochondria-derived peptide that translocates to nucleus under stress; activates AMPK pathway, regulates AICAR and folate-methionine cycle
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Foxo4-DRI
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
MOTS-c
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Foxo4-DRI
MOTS-c
Where to source these peptides
Foxo4-DRI
13 listed
Browse directory →
Providers offeringMOTS-c
181 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 22, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Foxo4-DRI vs MOTS-c — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/foxo4-dri/mots-c